journal of reports in cancer and treatmentjournal of reports in cancer and treatment

journal of reports in cancer and treatment28 May journal of reports in cancer and treatment

J Clin Oncol. 2021;20(3):1689. Even though pertuzumab [95, 96], trastuzumab emtansine (T-DM1) [97], and lapatinib [98, 99] were all investigated in several first-line and second-line trials, no survival improvement was observed in any of these trials. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. 3C). Onco Targets Ther. 2020;8(Suppl 1):A1. Ku G, et al. Your privacy choices/Manage cookies we use in the preference centre. Rapid developments are ongoing in the clinical use of ADCs and are now considered one of the current hot spots for antitumor drug development. Ann Oncol. 2015;21(15):33726. Clin Cancer Res. 2023;41(36_suppl):405736405736. Unauthorized use of these marks is strictly prohibited. 2019;25(23):7098112. Accessibility FGFR1 mutations, FGFR2 amplifications, and FGFR3 rearrangements are the most common FGFR alterations in GC [166]. Catenacci DVT, et al. J Clin Oncol. INTEGRATE IIa: a randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)a study led by the Australasian Gastro-intestinal Trials Group (AGITG). Arch Surg. Ann Oncol. 2020;21(8):106676. Genetics and molecular pathogenesis of gastric adenocarcinoma. Sahin U, et al. Oncotarget. 2021;149(6):132231. We thank our authors and referees for their valuable contributions and hope that our readers will find this Series on Cancer Therapy informative and inspiring. Chaganty BKR, et al. Haffner I, et al. Liu Y, et al. Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health. Additionally, trastuzumab beyond progression also failed to show a survival benefit in pre-treated HER2-positive GC patients in the T-ACT trial [100]. In this phase II study, the ORR was 77.8%, and the DCR was 92.6%, indicating the need for a future randomized clinical trial to confirm the efficacy of KN026 plus KN046 treatment versus standard of care. Experts want the U.S. government to protect the drug supply so that over 100,000 cancer patients can get life-saving drugs on . Raj S, et al. Yoshida K, et al. Other studies have also reported that deletion of ErbB2 16 exon and co-mutation and/or amplification of KRAS, HER3, EGFR, PI3K or PTEN could contribute to the resistance of anti-HER2 therapy [109, 113, 115, 116]. Molecular targeted therapy remains an essential treatment option for patients with advanced GC, aimed to inhibit tumor proliferation and increase survival rates. Lancet Oncol. 2019;20(3):42035. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Li S, et al. J Clin Oncol. The National Cancer Program that arose from this initiative resulted in a profound institutional reorganization within the National Institutes of Health, with the overarching goal of developing the infrastructures required for the treatment, cure, and elimination of cancer. Janjigian YY, et al. Also, one-stage surgical treatment of concomitant aneurysm of the abdominal aorta and gastric cancer is well tolerated and can avoid financial costs, and patient anxiety involved in a second operation. Lordick F, et al. 2019;30(9):147986. Unfortunately, both studies were terminated due to increased number of deaths in the rilotumumab group[180, 181]. Pietrantonio F, et al. Ohtsu A, et al. A randomized phase II study (FAST) indicated that zolbetuximab plus first-line chemotherapy significantly improved PFS and OS in patients with CLDN18.2-positive G/GEJ cancer [159]. 2021;11: 712760. Moehler MH, et al. Lancet Oncol. CAS Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. 2021;39(9):96677. Springer Nature. Lancet Oncol. PubMed Perko MJ, Schroeder TV, Olsen PS, Jensen LP, Lorentzen JE. A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the RILOMET-2 trial. INTEGRATE IIb ((NCT0487936)), an international randomized phase 3 trial, is ongoing to compare regorafenib plus nivolumab to standard chemotherapy in pre-treated patients with AGOC. JAMA Oncol. Laparotomy as a precipitating factor in the rupture of intra-abdominal aneurysms. Ann Oncol. Alcindor T, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiCa randomized phase III trial. Cancer Commun (Lond). Cancer treatment and survivorship statistics, 2019 The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. Gastric Cancer. Secondary pure red cell aplasia (PRCA) is a rare but recognized immune related adverse event. 2021;22(8):108192. The histological examination allowed to diagnose a low-grade adenocarcinoma of the stomach. 2016;7(22):3292532. Life (Basel), 2022;12(1). Online ahead of print. Onohara T, Orita H, Toyohara T, Sumimoto K, Wakasugi K, Matsusaka T, et al. Komori K, Okadome K, Itoh H, Funahashi S, Sugimachi K. Management of concomitant abdominal aortic aneurysm and gastrointestinal malignancy. A key example of how basic research on oncogenic alterations translated into substantial clinical benefits for a large number of patients is BCR-ABL1 tyrosine-kinase inhibitors for chronic myeloid leukemia. Cancer https://doi.org/10.1038/s43018-021-00181-0 (2021). Phase I Study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors. ISSN 2662-1347 (online). Cancer Discov. Berry LL, Davis SW, Godfrey Flynn A, Landercasper J, Deming KA. 2023 BioMed Central Ltd unless otherwise stated. Claudin 18.2 (CLDN18.2), a component of intercellular junctions [155], is exclusively detected in gastric mucosa and absent from other healthy tissues. Four lumbar arteries were stitched. A copy of the written consent is available for review by the Editor-in-Chief of this journal. 2015;18(3):45866. Guan WL, et al. Patients with CPS10 had better OS benefits than those with CPS1. Oncology Research and Treatment | Karger Publishers Google Scholar. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Efficacy of disitamab vedotin in treating HER2 2+/FISH- gastric cancer. 1967;95:40212. However, the addition of onartuzumab to mFOLFOX6 did not improve clinical outcomes in the ITT population or in the MET-positive population [179]. All rights reserved. CAS Wen-Long Guan and Ye He have contributed equally. Lancet Gastroenterol Hepatol. Thus, substantial progress has been made across first-line cancer therapy modalities. 2017;28(4):85561. Prospective observation: clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients. J Clin Oncol. PubMed Nevertheless, certain aspects of ADCs remain to be addressed. Gastric Cancer. Chen ZH, et al. and JavaScript. J Immunother Cancer. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. About This Journal. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. PubMed Central discovered that SRC-mediated persistent activation of the MAPK-ERK and PI3K-mTOR pathways was connected to the treatment resistance in HER2-positive GC cell lines [117]. Apatinib is a small molecule VEGFR inhibitor with China Food and Drug Administration (CFDA) approval for the treatment of advanced or metastatic chemotherapy-refractory GC. Previous large randomized clinical trials have failed to demonstrate any significant survival benefit with EGFR-targeted agents [92, 174], perhaps because most of the studies were performed in unselected patient populations regardless of EGFR status. Co-first authors: Simron Singh, MD MPH and Thomas A. Cancer Lett. Google Scholar. Gastric Cancer. Kang YK, et al. Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs) with several new agents approved for use. Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma. Privacy SHARED: Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy (cCRT) in patients with locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma. 2022;28(6):118998. J Clin Oncol. As a result, resistance to HER2-targeted therapy has been associated with the heterogeneity of HER2 expression [101, 104, 105]. A meta-analysis on alcohol drinking and gastric cancer risk. This site needs JavaScript to work properly. The advent of targeted therapy and immunotherapy has revolutionized the treatment of cancer, especially with the development and availability of sophisticated diagnostic and molecular characterization technologies. Transl Cancer Res. Cancer Discov. Piha-Paul S, et al. CCNE1 co-amplification has been found to be more strongly related to HER2-positive AGC than to HER2-positive breast cancer [112]. 2020;21(10):135365. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. J Clin Oncol. statement and J Clin Oncol. Andre T, et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. Lancet Oncol. Sign up for the Nature Briefing newsletter what matters in science, free to your inbox daily. Objective . A randomized phase III FRUTIGA study has investigated fruquintinib plus paclitaxel versus paclitaxel alone in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who had progressed after first-line standard chemotherapy (NCT03223376). First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: results from a phase I Study. AACR Journals Metrics | American Association for Cancer Research All authors contributed to this manuscript and revised the manuscript. 1998;85:118590. In the CheckMate-649 and ORIENT-16 studies, CPS5 was used as the cut-off value for the primary endpoint OS. Based on the safety and activity profile of bemarituzumab monotherapy in GC, the phase II FIGHT trial was designed to evaluate the efficacy of bemarituzumab plus mFOLFOX6 regimen in previously untreated, FGFR2b-overexpressing advanced-stage G/GEJ cancers [172]. Ann Oncol. 2023;41(2):25565. 2022;40(4_suppl):371. 2020;38(18):205361. Abdominal cavity was lavaged with 2L of antiseptic solutions. 2022;40(4_suppl):243243. 2015;34(3):47996. 2022;12(2):40215. Stat Med. In the EPOC1706 study, lenvatinib, an anti-angiogenic multiple receptor tyrosine kinase inhibitor, combined with pembrolizumab showed an exciting activity with an ORR of 69% in the first-line and second-line treatment of advanced GC[151]. Ychou M, et al. Explore the latest in cancer science including checkpoint inhibitors, DCIS, breast prostate and lung cancer treatment, aspirin prevention, biomarkers, and more. Novel diagnostic techniques have contributed to characterizing the genetic profile of GC and identifying new potential molecular targets. Most GC patients are not susceptible to immune checkpoint inhibitor monotherapies. Privacy The journal will not consider Case Reports or articles related to Cancer Policy. Cancer Commun (Lond). 2019;106(11):94658. Sanchez-Vega F, et al. National Library of Medicine Altogether, these findings suggested that MSI-H status was a predictive biomarker for immune checkpoint inhibitor treatments, regardless of the line of therapy. Advancing Cancer Therapy. According to a phase I study, ZW25 was well tolerated with durable response in heavily pretreated GEA patients (including prior HER2-targeted therapy) [86]. The postoperative period proceeded without features and complications. 2019;37(15_suppl):40174017. 2019;19(1):494. 2019;30(9):148795. The postoperative period proceeded without features and complications. Chemotherapy for advanced gastric cancer. 2021;39(13):146878. We expect that extensive translational research, preclinical investigations, and multi-omics-based clinical trials will lead to breakthroughs in the diagnosis and treatment of GC. Moehler MH, et al. 2021;18(8):47387. To overcome intrinsic and acquired resistance to trastuzumab, various clinical trials have explored newer agents and combinations. 2014;15(8):894904. 2021;14(1):23. Would you like email updates of new search results? Since the second half of the twentieth century, no more than 30 observations of simultaneous operations for abdominal aortic aneurysm and gastric cancer have been described in the world literature [8]. On computed tomography (CT) (Fig. For resectable GC, perioperative chemotherapy has become . Unlike T-DM1, disitamab vedotin has a bypass-killing effect on nearby tumor cells regardless of HER2 status, which could help overcome spatial heterogeneity and enhance anti-tumor effects. J Clin Oncol. Cookies policy. Surveillance Research Program, National Cancer Institute. Google Scholar. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer treatment and survivorship statistics, 2016. J Immunother Cancer. J Clin Oncol. 2020;11(1):525. Accepted manuscripts They can be cited using the author(s), article title, journal title, year of online publication, and DOI. Catenacci DVT, et al. Arch Surg. Xu R-h, et al. Rui-Hua Xu. A comprehensive analysis of patients with CPS10 in KEYNOTE-059, 061 and 062 also showed consistent improvement toward better outcomes with pembrolizumab in different lines of treatment in this subgroup [85]. Am J Clin Pathol. The existence of persistent ctDNA following curative-intent treatment of GC may indicate minimal residual disease, and trials are underway to determine whether additional adjuvant therapy can result in the clearance of ctDNA. Swanson RJ, Littooy FN, Hunt TK, Stoney RJ. Janjigian YY, et al. 2013;381(9864):40012. Article 2021;41(11):117382. Correspondence to The neoplasm made it difficult to insert an endoscope into the stomach. Oncol.2021;39(3_suppl):218. Shinde A, et al. Casak SJ, et al. Different types of FGFR targeting agents were explored or developed in GC, including multikinase inhibitors, pan-FGFR inhibitors, FGFR1-3 inhibitors, selective FGFR inhibitors and ADC. 2013;8(3): e54014. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100. Recently, many novel immune checkpoint modulators have been widely investigated, including LAG-3, VISTA, TIM-3, TIGIT, CD38, CD39, and CD73[190]. In 8 of 29 distant lymph nodes, cancer metastases were present (pT3N3aM0 R0 stage IIIB TNM 8). Google Scholar. Your privacy choices/Manage cookies we use in the preference centre. When choosing a surgical access, there is an opinion that it is advisable to perform gastrectomy through midline laparotomy, while aortic prosthetics is recommended to perform using retroperitoneal access, in order to reduce the risk of aortic graft contamination [14]. In a phase II clinical study, KN026 showed favorable results in patients with HER2-overexpressing G/GEJ adenocarcinoma (IHC3+or IHC 2+ISH+) with an ORR of 56% [127]. Gastric cancer treatment: recent progress and future perspectives. 2019;49(9):8706. Claudin 18.2 served as a new target for the later-line treatment of GC, with considerable ORR improvement achieved in Claudin 18.2 CAR-T therapy, which has become a hallmark event for cellular immunotherapy in solid tumors. 2020;9(5):336774. 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. GenesisCare, a global provider of cancer-treatment services backed by private-equity firm KKR, has filed for bankruptcy with plans to look for a buyer for its U.S. business. Interventions: Four cycles of carboplatin and docetaxel chemotherapy reduced the size of the tumor; however, it increased in size after 8 months, and re-challenge chemotherapy (RC) with the same drugs was performed. Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. It is a first-in-class afucosylated monoclonal antibody against the FGFR2b splice variant frequently overexpressed in FGFR2- amplified G/GEJ cancers. Lancet Oncol. Clipboard, Search History, and several other advanced features are temporarily unavailable. NRF2 through RPS6 activation is related to anti-HER2 drug resistance in HER2-amplified gastric cancer. Careers. Bang YJ, et al. Wei Wang MM. INTRODUCTION Types of Articles Prior Publication Submission Checklist BEFORE YOU BEGIN Ethics in publishing Studies in humans and animals Informed consent and patient details Declaration of competing interest Declaration of generative AI in scientific writing Submission declaration and verification Use of inclusive language 2. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. 2008;14(23):762434. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. The incidence of MSI-H status in GC was reported to range from 8 to 25%, which was much lower in metastatic disease [74].

Pink Current Interactive Brokers, Alien Goddess Fragrancenet, Articles J